Reading INCY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track INCY free→Reading INCY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track INCY free→QuarterlyIQ Insights · INCY
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On April 28, 2026 , Incyte Corporation issued a press release announcing financial results for its first fiscal quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1.
Director — Susanne Schaffert: Dr. Susanne Schaffert resigned from the Board of Directors.
President, Incyte and Global Head of Research and Development — Pablo J. Cagnoni: Title changes for certain members of the executive leadership team, including an internal promotion.
Other Events. On February 27, 2026, the U.S. Food and Drug Administration (“FDA”) issued a Complete Response Letter (“CRL”) for the supplemental Biologics License Application (“sBLA”) for Zynyz® (retifanlimab-dlwr) injection (375mg) for an additional indication for the treatment of adult patients with metastatic non-small cell lung cancer (“NSCLC”) in combination with platinum-based chemotherapy. The sBLA was supported by positive efficacy and safety data from the Phase 3 POD1UM-304 trial ann…
Results of Operations and Financial Condition. On February 10, 2026, Incyte Corporation issued a press release announcing financial results for its fourth fiscal quarter and year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1.
Director — Hervé Hoppenot: The former CEO is retiring from the Board of Directors.
principal financial officer — Thomas Tray: An existing executive was promoted to an additional role.
Chief Financial Officer — Christiana Stamoulis: Ms. Stamoulis is leaving to pursue another opportunity.
Other Events On May 11, 2025, Incyte Corporation (the “Company”) and Novartis Pharma AG (“Novartis”) entered into a settlement agreement (the “Settlement Agreement”) with respect to litigation initiated by Novartis and relating to the duration of royalty payments owed by the Company to Novartis under the Collaboration and License Agreement dated November 24, 2009, as amended, between the Company and Novartis. As of March 31, 2025, the Company had approximately $537.1 million of accrued royalt…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 6, 2025, Barry P. Flannelly, Executive Vice President, General Manager, North America of Incyte Corporation (the “Company”), announced his retirement from the Company and stepped down from that role on that date, effective with the commencement of employment of his successor. Dr. Flannelly will remain employed by the Company through July…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in
Entry Into a Material Definitive Agreement . On June 28, 2024, Incyte Corporation (the “Company”) and its subsidiary, Incyte Holdings Corporation (“Incyte Holdings”), entered into Amendment No. 2 (“Amendment No. 2”) to the Revolving Credit and Guaranty Agreement dated as of August 21, 2021 among the Company, as borrower, Incyte Holdings, as a guarantor, the lenders from time to time party thereto, J.P. Morgan Chase Bank, N.A. as administrative agent, and the other financial institutions party…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . On September 8, 2023, Maria E. Pasquale, Executive Vice President, General Counsel and Corporate Secretary of Incyte Corporation (the “Company”), notified the Company of her intention to retire effective November 1, 2023. Ms. Pasquale’s roles as Executive Vice President, General Counsel and Corporate Secretary of the Company may end earlier than h…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . Election of Directors Effective October 1, 2022, the Board of Directors of Incyte Corporation (the “Company”) increased the number of authorized members of the Board of Directors of the Company to nine and elected Susanne Schaffert, Ph.D., a member of the Board of Directors of the Company. Dr. Schaffert, age 55, previously spent 26 years at the ph…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Director Retirement On April 18, 2022, Wendy L. Dixon notified Incyte Corporation (the “Company”) that she will be retiring from the Company’s Board of Directors, effective at the time of the Company’s 2022 Annual Meeting of Stockholders. Dr. Dixon has been a member of the Company’s Board of Directors since 2010. 2 SIGNATURE Pursuant to the require…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 10, 2022, Paul Trower notified Incyte Corporation (the “Company”) of his intention to retire as Division Vice President, Finance and Principal Accounting Officer of the Company effective March 11, 2022. Effective March 11, 2022, the board of directors of the Company appointed Thomas Tray, age 44, as the Company’s Vice President, Finance…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . Election of Directors Effective September 27, 2021, the Board of Directors of Incyte Corporation (the “Company”) increased the number of authorized members of the Board of Directors of the Company to nine and elected Otis W. Brawley, M.D., a member of the Board of Directors of the Company. Dr. Brawley, age 62, has served as a Bloomberg Distinguish…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in
Entry Into a Material Definitive Agreement. On August 18, 2021, Incyte Corporation (the “Company”) and its subsidiary, Incyte Holdings Corporation (“Incyte Holdings”), entered into a revolving credit and guaranty agreement (the “Credit Agreement”) among the Company, as borrower, Incyte Holdings, as a guarantor, the lenders from time to time party thereto (the “Lenders”), J.P. Morgan Chase Bank, N.A. as administrative agent, and the other financial institutions party thereto. Under the Credit…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.